The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michael, A. F.
Right arrow Articles by Vernier, R. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Michael, A. F.
Right arrow Articles by Vernier, R. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Journal of Experimental Medicine, Vol 134, 208-227, Copyright © 1971 by The Rockefeller University Press


IMMUNE COMPLEXES AND GLOMERULONEPHRITIS IN MAN

STUDIES ON CHRONIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS WITH HYPOCOMPLEMENTEMIA

Alfred F. Michael 1, N. Gunnar Westberg 1, Alfred J. Fish 1, and Robert L. Vernier 1

1 From the Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota 55455

CMPGN with hypocomplementemia appears to be one identifiable form of progressive and destructive glomerulonephritis, but whether this is a specific pathogenetic entity has not been proven. The clinical features of the "disease" include presentation with either asymptomatic proteinuria and hematuria, nephrotic syndrome, or gross hematuria and an acute nephritic syndrome. Morphologic studies reveal extensive mesangial cell proliferation and increased matrix with thickening of the glomerular capillary. Deposits of C3 and properdin uniformly are found predominantly in a peripheral lobular distribution by immunofluorescent microscopy; immunoglobulins are seen less consistently. These deposits are different from those seen in other glomerular diseases.

Serum complement abnormalities have also been demonstrated: depression of C3t (and ß1C/ß1A) with relatively normal earlier components, evidence for in vivo breakdown of C3 by labeled isotope studies and elevated alpha2D, presence of a serum inhibitor that inactivates guinea pig C3t and a pseudoglobulin lytic factor that in combination with a normal serum cofactor enzymatically cleaves C3 to alpha2D and ß1A.

The terminal complement inactivation and the uniform presence of properdin in these deposits suggesting an alternate pathway of immune injury must be balanced against immunopathologic observations which demonstrate glomerular deposits of immunoglobulins and earlier complement components. It is possible that both mechanisms may be operative in CMPGN.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS